Alzheimer's Disease Cooperative Study

Last updated

The Alzheimer's Disease Cooperative Study (ADCS) was founded at University of California San Diego in 1991 and coordinates clinical trials of candidate treatments for Alzheimer's disease. It is funded by the National Institutes of Health as well as companies that develop drugs. As of 2008, 75 research sites in the United States and Canada were part of the consortium. Leon Thal served as director until February 2007, when he died; Paul Aisen was recruited to succeed him. In 2006, the NIH awarded $52 million to ADCS to fund 6 years of further clinical trials. [1]

In 2013 Eli Lilly committed to spending $76.6 million on clinical trials through the center. [2]

The center has coordinated important clinical trials on AD drugs like solanezumab. [3]

Aisen left UCSD in 2015 because he was unhappy with the level of support that UCSD was providing him and due to USC's offer. [4] UCSD and USC ended up in litigation over control of the ADCS and its research data, which at that time involved six ongoing clinical trials and data collected on thousands of clinical trial subjects. [5] [6] Part of the dispute arose because Aisen's lab had uploaded the data from the ADCS onto Amazon Cloud servers and would not give the passwords to UCSD officials. [3] [7] [8] Some aspects of data management were temporarily settled in 2016; [9] as of 2017 the litigation was ongoing. [10] [11] The lawsuit was settled in 2019. [12]

Related Research Articles

The California Institute for Regenerative Medicine (CIRM) was created in 2004 after 59% of California voters approved California Proposition 71: the Research and Cures Initiative, which allocated $3 billion to fund stem cell research in California.

The Keck School of Medicine of the University of Southern California teaches and trains physicians, biomedical scientists and other healthcare professionals, conducts medical research, and treats patients. Founded in 1885, it is the second oldest medical school in California after the UCSF School of Medicine.

<span class="mw-page-title-main">UC San Diego Health</span> Hospital in San Diego, California

UC San Diego Health is the academic health system of the University of California, San Diego in San Diego, California. It is the only academic health system serving San Diego and has one of only two adult Level I trauma centers in the region. In operation since 1966, it comprises UC San Diego Medical Center in Hillcrest as well as Jacobs Medical Center, Moores Cancer Center, Shiley Eye Institute, Sulpizio Cardiovascular Center, and Koman Family Outpatient Pavilion, all located in La Jolla. It also includes several outpatient sites located throughout San Diego County. The health system works closely with the university's School of Medicine and Skaggs School of Pharmacy to provide training to medical and pharmacy students and advanced clinical care to patients.

Beta-secretase 1

Beta-secretase 1, also known as beta-site amyloid precursor protein cleaving enzyme 1, beta-site APP cleaving enzyme 1 (BACE1), membrane-associated aspartic protease 2, memapsin-2, aspartyl protease 2, and ASP2, is an enzyme that in humans is encoded by the BACE1 gene. Expression of BACE1 is observed mainly in neurons.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

Lawrence S.B. Goldstein is a professor of cellular and molecular medicine at University of California, San Diego and investigator with the Howard Hughes Medical Institute. He receives grant funding from the NIH, the Johns Hopkins ALS Center, the HighQ Foundation, and the California Institute for Regenerative Medicine. In 2020 he was elected to the National Academy of Sciences.

<span class="mw-page-title-main">UC San Diego School of Medicine</span> Medical school of UC San Diego

The University of California San Diego School of Medicine is the graduate medical school of the University of California, San Diego. It was the third medical school in the University of California system, after those established at UCSF and UCLA, and is the only medical school in the San Diego metropolitan area. It is closely affiliated with the medical centers that are part of UC San Diego Health.

<span class="mw-page-title-main">Amylin Pharmaceuticals</span> Biopharmaceutical company

Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company was engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Amylin produced three drugs: Symlin, Byetta (exenatide) and Bydureon.

Ivor Royston Researcher

Ivor Royston, M.D., is an oncologist, researcher, scientist, entrepreneur and venture capitalist, recognized for his efforts to develop treatments for multiple disease targets and to fund biotechnology companies with promising science, technology or medicines. He speaks regularly at healthcare conferences and symposia throughout the United States, Europe and Asia.

Semagacestat

Semagacestat (LY-450139) was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Elan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients, but in August 2010, a disappointing interim analysis, in which semagacestat performed worse than the placebo, led to the trials being stopped.

Solanezumab is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector for patients with Alzheimer's disease. The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials.

Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study that aims to improve clinical trials for the prevention and treatment of Alzheimer's disease (AD). This cooperative study combines expertise and funding from the private and public sector to study subjects with AD, as well as those who may develop AD and controls with no signs of cognitive impairment. Researchers at 63 sites in the US and Canada track the progression of AD in the human brain with neuroimaging, biochemical, and genetic biological markers. This knowledge helps to find better clinical trials for the prevention and treatment of AD. ADNI has made a global impact, firstly by developing a set of standardized protocols to allow the comparison of results from multiple centers, and secondly by its data-sharing policy which makes available all at the data without embargo to qualified researchers worldwide. To date, over 1000 scientific publications have used ADNI data. A number of other initiatives related to AD and other diseases have been designed and implemented using ADNI as a model. ADNI has been running since 2004 and is currently funded until 2021.

Anders Martin Dale is a prominent neuroscientist and professor of radiology, neurosciences, psychiatry, and cognitive science at the University of California, San Diego (UCSD), and is one of the world's leading developers of sophisticated computational neuroimaging techniques. He is the founding Director of the Center for Multimodal Imaging Genetics (CMIG) at UCSD.

Lanabecestat Chemical compound

Lanabecestat is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor. A BACE inhibitor in theory would prevent the buildup of beta-amyloid and may help slow or stop the progression of Alzheimer's disease.

<span class="mw-page-title-main">RIMAC</span>

The Recreation, Intramural, and Athletic Complex is a sports complex at the University of California San Diego comprising an arena, a weight room and various other event and athletic facilities. It is one of the largest college athletic facilities in the country. RIMAC Arena is the home arena of the UC San Diego Tritons men's and women's basketball and volleyball teams, and Triton Soccer Stadium on the adjacent RIMAC Field hosts Triton men's and women's soccer matches.

<span class="mw-page-title-main">Don W. Cleveland</span>

Don W. Cleveland is an American cancer biologist and neurobiologist.

Verubecestat Chemical compound

Verubecestat (MK-8931) was an experimental drug for the treatment of Alzheimer's disease. It is an inhibitor of beta-secretase 1 (BACE1), which, after initial promise proved disappointing.

Steven M. Paul is an American neuroscientist and pharmaceutical executive. As of 2021, Paul serves as the CEO, president and chairman of Karuna Therapeutics.

Paul Stephen Aisen is an American physician and medical researcher. He started his career as a rheumatologist and then made Alzheimer's disease his focus. As of 2015 he was on the faculty of the Keck School of Medicine of USC and his offices were in San Diego.

Cheryl Ann Marie Anderson is an American epidemiologist. Anderson is a professor at and founding Dean of the University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science. Anderson's research focus is on nutrition and chronic disease prevention in under-served human populations.

References

  1. ↑ "Paul Aisen, MD, Joins Faculty of UCSD and is Appointed New Director of the Alzheimer's Disease Cooperative Study". Journal of Investigative Medicine. 56 (1): 3. January 2008. doi:10.1097/01.JIM.0000308082.54350.ba.
  2. ↑ Terry, Mark (July 22, 2015). "Eli Lilly Increases San Diego R&D Space by 140%, Staff by 70%". BioSpace via PharmaLive.
  3. 1 2 Garde, Damian (August 5, 2015). "Judge orders a halt to Alzheimer's spat as Eli Lilly chooses sides in dispute". FierceBiotech.
  4. ↑ Fikes, Bradley J. (5 July 2015). "UC San Diego sues USC and scientist, alleging conspiracy to take funding, data". Los Angeles Times.
  5. ↑ Check Hayden, Erika (16 July 2015). "Alzheimer's data lawsuit is sign of growing tensions". Nature. pp. 265–265. doi:10.1038/nature.2015.17932.
  6. ↑ Basken, Paul (23 July 2015). "Grant Dispute Throws an Unwritten Rule of Academic Poaching Out the Window". The Chronicle of Higher Education.
  7. ↑ Fikes, Bradley J. (2 August 2015). "Next steps for scientist in eye of UCSD-USC Alzheimer's spat". San Diego Tribune.
  8. ↑ Wang, Shirley S.; Loftus, Peter (14 October 2015). "Alzheimer's Research Effort Is Ensnared in Legal Dispute". Wall Street Journal.
  9. ↑ Potter, Matt (January 11, 2016). "Deal gives UCSD "read only" rights to Alzheimer's data". San Diego Reader.
  10. ↑ "Case 3:15-cv-01766: The Regents of the University of California v. Aisen et al (3:15-cv-01766), California Southern District Court". PacerMonitor. Retrieved 15 June 2017.
  11. ↑ "Case 8:17-cv-00721: The Regents of the University of California v. Aisen et al (8:17-cv-00721), Maryland District Court". PacerMonitor. Retrieved 15 June 2017.
  12. ↑ "USC pays UCSD $50M, and gives the school an apology, for raiding its Alzheimer's program". San Diego Union-Tribune. 2019-07-04. Retrieved 2022-09-14.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.